查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1565060

心臟泵的世界市場

Heart Pump Devices
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球心臟幫浦市場將達到 85 億美元

2023年全球心臟幫浦市場預估為27億美元，預估至2030年將達85億美元，2023-2030年分析期間複合年增率為17.6%。心室輔助裝置 (VAD) 是本報告分析的細分市場之一，預計複合年成長率為 19.4%，到分析期結束時將達到 51 億美元。主動脈內球囊幫浦 (IABP) 細分市場在分析期間的複合年成長率預計為 14.8%。

美國市場預計將達到7.285億美元，中國預計複合年成長率為16.6%。

預計 2023 年美國心臟幫浦市場規模將達 7.285 億美元。中國作為世界第二大經濟體，預計2030年市場規模將達13億美元，2023-2030年分析期間複合年成長率為16.6%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 15.9% 和 14.5%。在歐洲，德國預計複合年成長率為 11.4%。

全球心臟幫浦市場－主要趨勢與促進因素總結

為什麼心臟幫浦對於治療進行性心臟衰竭、支持心血管手術和提高患者存活率變得至關重要？

心臟幫浦對於治療晚期心臟衰竭、支持心血管手術和提高患者存活率至關重要。但為什麼這些設備在今天如此重要？隨著全球心臟衰竭盛行率的增加，我們提供的左心室輔助裝置 (LVAD) 和全人工心臟 (TAH) 等心臟幫浦是藥物和常規治療方法無效的患者的挽救生命的解決方案。這些輔助人工心臟透過幫助心臟更有效地泵血來幫助衰竭的心臟，確保重要器官繼續獲得足夠的氧氣和營養，或對於完全替換非常重要。對於許多患有末期心臟衰竭的患者來說，心臟泵是他們在等待心臟移植期間保持生命的唯一可行選擇，或者在無法進行移植時作為長期替代方案。

除了治療心臟衰竭外，心臟幫浦在支持接受高風險心血管手術的患者方面也發揮著重要作用。在此類手術中，心臟幫浦提供的臨時機械循環支援可確保維持血流並降低手術期間和術後併發症的風險。它也擴大用於穩定病情嚴重的患者，例如那些從心臟病發作或心源性休克恢復的患者，這些患者的心臟無法自行泵出足夠的血液。

此外，心臟幫浦可透過減少疲勞、呼吸急促和體液儲存等症狀，顯著改善心臟衰竭患者的生活品質。透過支持心臟功能，患者可以在日常生活中生活得更舒適，並改善他們的身心健康。

技術進步和創新如何提高心臟幫浦的效率、安全性和壽命？

技術進步和創新顯著提高了心臟幫浦的效率、安全性和壽命，使其對心臟衰竭患者更加可靠和有效。最有影響力的創新之一是開發更小、更耐用、侵入性更小的左心室輔助循環裝置 (LVAD)。這些新一代 LVAD 的植入手術風險較低，並為患者提供更好的治療效果。小型化方面的創新使這些設備能夠與更廣泛的患者相容，包括那些由於先前型號的尺寸而可能無法成為候選者的患者。這些小型化設備也最大限度地減少了大型外科手術的需要，從而減少了感染疾病和血栓等併發症。

心臟幫浦技術的另一項重大進步是提高能源效率和電池壽命。前幾代心臟幫浦需要患者攜帶外部電池，限制了移動性和便利性。如今，先進的電池技術可以提供更持久的攜帶式電源，從而減少頻繁更換電池和充電的需要。一些設備也正在研究無線充電技術，該技術可以消除對外部電源線的需求，並進一步提高患者的生活品質。這些改進使心臟泵更加實用且要求更低，使患者能夠更自由地活動並過上更獨立的生活。

人工智慧（AI）和資料分析的整合也是心臟泵的關鍵創新。人工智慧驅動的監控系統可以持續追蹤設備性能和患者生理參數，及早發現潛在問題並提醒醫療保健提供者註意故障或惡化的徵兆。這些智慧型系統有助於最佳化設備設定並進行即時調整，以保持您的心臟幫浦以最高效率運作。人工智慧演算法還可以預測患者何時需要醫療干預，改善長期結果並降低併發症的風險。

生物相容性材料也是心臟幫浦有重大改進的一個領域。這些設備中使用的新材料可降低血液凝固（血栓症）和感染的風險，這是與心臟幫浦相關的常見併發症。使用模仿人體組織的先進塗層和材料可以最大限度地減少免疫系統對設備的反應，從而減少對血液稀釋劑和其他藥物的需求。這不僅提高了患者的安全，還透過減少磨損來延長設備的使用壽命。

遠端監控功能也正在改變心臟幫浦的管理方式。現在可以透過連網型的健康平台遠端監控裝有心臟泵的患者，從而使醫療保健提供者能夠即時追蹤設備性能和患者健康指標。這樣可以及早發現潛在問題，減少親自到診所就診的頻率，並讓患者和臨床醫師安心。此外，遠端監控的進步使患者更容易接受個人化治療和量身定做的治療計劃，而無需頻繁住院。

為什麼心臟幫浦對於減少心臟衰竭患者的再入院率、延長預期壽命和改善生活品質很重要？

心臟幫浦對於減少心臟衰竭患者的再入院率、延長預期壽命和改善生活品質至關重要。心臟幫浦有價值的主要原因之一是它們可以減少慢性心臟衰竭患者的再入院頻率。心臟衰竭的特徵是心臟泵血能力減弱，導致症狀反覆和頻繁住院。心臟幫浦透過持續支持心臟功能、穩定患者病情並減少頻繁醫療干預的需要來緩解這種情況。這不僅提高了患者的生活品質，還透過降低對緊急護理和醫院資源的需求，減輕了醫療保健系統的負擔。

延長使用壽命也是心臟幫浦的主要優點。在缺乏先進治療方法的情況下，末期心臟衰竭患者的預期壽命通常僅限於數月至數年。心臟泵，特別是 LVAD，已被證明可以透過在患者等待心臟移植時支持心臟功能或在無法進行移植時作為長期治療來顯著延長生存期。患有 LVAD 的患者通常能夠使用該設備生活數年，使他們有時間接受其他治療並維持更好的生活品質。

改善心臟衰竭患者的生活品質是心臟幫浦的一個重要好處。心臟衰竭嚴重限制患者的日常生活，導致疲勞、呼吸急促以及參與身體活動的能力下降。透過改善血流，心臟幫浦可以緩解這些症狀並幫助患者恢復體力和精力。因此，患者能夠過著更積極的生活，參與社會活動，並獲得更大的獨立感。許多安裝了心臟泵的患者表示，佩戴心臟泵後，他們的身心健康得到了顯著改善。

心臟幫浦也為不適合心臟移植的患者提供了另一種選擇。有些患者因各種原因不適合心臟移植，包括年齡、併發症以及是否有捐贈心臟。在這些情況下，心臟幫浦可以作為長期解決方案，為心臟提供機械支持，讓患者活得更長久、更健康。這對於老年患者和患有其他使移植候選變得複雜的疾病的患者尤其有價值。

除了治療心臟衰竭之外，心臟幫浦還可以幫助預防與其他心血管疾病相關的併發症，例如心源性休克和心臟病發作。透過在這些關鍵事件期間提供機械循環支持，心臟幫浦可以穩定患者，防止心臟進一步受損，提高整體存活率，並降低長期併發症的風險。

推動心臟幫浦市場成長的因素有哪些？

推動心臟幫浦市場快速成長的幾個關鍵因素包括心臟衰竭盛行率的增加、心臟幫浦技術的進步、全球人口老化以及對機械循環支援的需求不斷成長。主要促進因素之一是全球心臟衰竭盛行率的增加。隨著人口老化以及肥胖、高血壓和糖尿病等生活方式因素變得越來越普遍，心臟衰竭的人數正在穩定增加。這就產生了對先進治療方案的巨大需求，例如心臟泵，它可以為對藥物治療或微創治療方法無反應的患者提供有效的長期解決方案。

心泵技術的進步也是推動市場成長的主要因素。更小、更耐用、侵入性更小的設備的開發使得心臟泵可供更廣泛的患者使用，包括心臟衰竭不太嚴重的患者和不適合使用老一代設備的患者。這些技術進步也改善了患者的治療效果、減少了併發症並提高了存活率，推動了心臟幫浦在世界各地醫療保健系統中的採用。

全球人口老化也促進了心泵市場的成長。隨著預期壽命的不斷延長，包括心臟衰竭在內的與老齡化相關的心血管疾病的發生率也在增加。老年患者更有可能患有心臟衰弱的疾病，這使他們成為心臟泵的良好人選。預計未來幾十年老年人數量將顯著增加，從而增加對心臟泵作為老齡化相關心臟衰竭治療選擇的需求。

此外，短期和長期情況下對機械循環輔助設備的需求不斷成長也是推動市場成長的因素。心臟幫浦擴大用於重症加護環境，例如高風險心血管手術期間以及從心臟病發作或心源性休克中恢復的患者。心臟幫浦穩定患者和支持復健的能力使其成為心臟病專家和心臟外科醫生的寶貴工具，推動醫院和醫療機構進一步採用。

人們日益關注改善慢性心臟病患者的生活品質也推動了市場的發展。心臟幫浦被認為是治療心臟衰竭的重要選擇，因為患者和醫療保健提供者尋求不僅可以延長壽命而且可以改善日常功能的解決方案。這些設備所提供的患者活動能力、症狀緩解和整體生活品質的改善是增加使用的主要動力。

此外，政府對心臟泵的支持和監管核准正在擴大這些救生技術的使用範圍。美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構擴大核准新的心臟幫浦和創新技術，使這些技術能夠更廣泛地應用於醫療保健提供者和患者。此類監管支援對於推動市場擴張和加速下一代心臟泵技術的開發至關重要。

總之，心臟衰竭衰竭盛行率上升、技術進步、全球人口老化以及對機械循環支援的需求不斷增加推動了心臟泵市場的成長。心臟幫浦繼續被醫療保健系統採用，作為先進心臟病管理的關鍵解決方案，它們正在提高患者的生存率，減少再入院率，並心臟衰竭。越來越重要的作用。

調查企業舉例（共13家）

  • Abbott Laboratories
  • Abiomed, Inc.
  • Berlin Heart GmbH
  • Fresenius Medical Care AG & Co. KGaA
  • Getinge AB
  • Jarvik Heart, Inc.
  • Medtronic PLC
  • ReliantHeart, Inc.
  • SynCardia Systems, LLC
  • Teleflex Incorporated
  • Terumo Europe NV

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP12313

Global Heart Pump Devices Market to Reach US$8.5 Billion by 2030

The global market for Heart Pump Devices estimated at US$2.7 Billion in the year 2023, is expected to reach US$8.5 Billion by 2030, growing at a CAGR of 17.6% over the analysis period 2023-2030. Ventricular Assist Devices (VADs), one of the segments analyzed in the report, is expected to record a 19.4% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Intra-aortic Balloon Pumps (IABPs) segment is estimated at 14.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$728.5 Million While China is Forecast to Grow at 16.6% CAGR

The Heart Pump Devices market in the U.S. is estimated at US$728.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.9% and 14.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.4% CAGR.

Global Heart Pump Devices Market - Key Trends and Drivers Summarized

Why Are Heart Pump Devices Becoming Essential for Treating Advanced Heart Failure, Supporting Cardiac Surgeries, and Improving Patient Survival Rates?

Heart pump devices have become essential for treating advanced heart failure, supporting cardiac surgeries, and improving patient survival rates. But why are these devices so critical today? With the rising prevalence of heart failure globally, heart pump devices, such as left ventricular assist devices (LVADs) and total artificial hearts (TAHs), are providing life-saving solutions for patients who are no longer responsive to medication or traditional therapies. These devices are crucial in assisting or completely replacing the function of a failing heart by helping it pump blood more effectively, ensuring that vital organs continue to receive sufficient oxygen and nutrients. For many patients with end-stage heart failure, heart pump devices are the only viable option to sustain life while waiting for a heart transplant or as a long-term alternative when transplants are not an option.

In addition to managing heart failure, heart pump devices play a vital role in supporting patients undergoing high-risk cardiac surgeries. In such procedures, temporary mechanical circulatory support provided by heart pump devices ensures that blood flow is maintained, reducing the risk of complications during and after surgery. These devices are also being increasingly used to stabilize patients in critical conditions, such as those recovering from heart attacks or cardiogenic shock, where the heart cannot pump enough blood on its own.

Moreover, heart pump devices significantly improve the quality of life for heart failure patients by reducing symptoms like fatigue, shortness of breath, and fluid retention. By supporting the heart’s function, these devices allow patients to engage in everyday activities with greater ease, improving both physical and mental well-being.

How Are Technological Advancements and Innovations Enhancing the Efficiency, Safety, and Longevity of Heart Pump Devices?

Technological advancements and innovations are significantly enhancing the efficiency, safety, and longevity of heart pump devices, making them more reliable and effective for patients with heart failure. One of the most impactful innovations is the development of smaller, more durable, and less invasive left ventricular assist devices (LVADs). These newer-generation LVADs are designed to be implanted with fewer surgical risks and provide better outcomes for patients. Innovations in miniaturization have allowed these devices to fit into a broader range of patients, including those who previously might not have been candidates due to the size of earlier models. These smaller devices also cause fewer complications, such as infections or blood clots, by minimizing the need for extensive surgical procedures.

Another significant advancement in heart pump technology is the improvement of energy efficiency and battery life. Earlier generations of heart pump devices required external batteries that patients had to carry with them, limiting mobility and convenience. Today, advanced battery technologies allow for longer-lasting, portable power supplies, reducing the need for frequent battery changes or recharging. Some devices are even exploring wireless charging technologies, which would eliminate the need for external power cables and further enhance the patient’s quality of life. These improvements make heart pump devices more practical and less burdensome, allowing patients to move more freely and live more independently.

The integration of artificial intelligence (AI) and data analytics is another key innovation in heart pump devices. AI-powered monitoring systems can continuously track the device's performance and the patient’s physiological parameters, detecting potential issues early and alerting healthcare providers to any signs of malfunction or deterioration. These intelligent systems help optimize device settings and make real-time adjustments to ensure the heart pump is working at peak efficiency. AI algorithms can also predict when a patient may need medical intervention, improving long-term outcomes and reducing the risk of complications.

Biocompatible materials are another area where heart pump devices are seeing significant improvements. New materials used in these devices reduce the risk of blood clotting (thrombosis) and infection, which are common complications associated with heart pumps. The use of advanced coatings and materials that mimic the body’s tissues minimizes the immune system’s response to the device, reducing the need for blood thinners and other medications. This not only enhances patient safety but also extends the longevity of the device by reducing wear and tear.

Remote monitoring capabilities are also transforming the way heart pump devices are managed. Patients with heart pumps can now be monitored remotely through connected health platforms, where healthcare providers can track device performance and patient health metrics in real-time. This allows for early detection of potential issues, reduces the frequency of in-person clinic visits, and provides peace of mind to both patients and clinicians. In addition, advancements in remote monitoring are making it easier for patients to receive personalized care and adjustments to their treatment plans without the need for frequent hospital stays.

Why Are Heart Pump Devices Critical for Reducing Hospital Readmissions, Extending Life Expectancy, and Enhancing Quality of Life for Heart Failure Patients?

Heart pump devices are critical for reducing hospital readmissions, extending life expectancy, and enhancing the quality of life for heart failure patients because they provide a long-term solution for those with severe heart conditions. One of the primary reasons heart pump devices are so valuable is their ability to reduce the frequency of hospital readmissions in patients with chronic heart failure. Heart failure is often characterized by recurring symptoms, leading to repeated hospitalizations as the heart becomes less effective at pumping blood. Heart pump devices alleviate this by consistently supporting the heart’s function, stabilizing the patient’s condition, and reducing the need for frequent medical interventions. This not only improves the patient’s quality of life but also reduces the strain on healthcare systems by lowering the demand for emergency care and hospital resources.

Extending life expectancy is another significant benefit of heart pump devices. For patients with end-stage heart failure, life expectancy is often limited to a few months or years without advanced treatment options. Heart pump devices, particularly LVADs, have been shown to significantly extend survival rates by supporting heart function while patients wait for a heart transplant or as a long-term therapy when transplantation is not feasible. In many cases, patients with LVADs can live for several years with the device, providing them with more time to receive other treatments or maintain a better quality of life.

Enhancing the quality of life for heart failure patients is a key advantage of heart pump devices. Heart failure can severely limit a patient’s ability to perform daily activities, leading to fatigue, shortness of breath, and a reduced ability to participate in physical activities. Heart pump devices help alleviate these symptoms by improving blood flow, allowing patients to regain their strength and energy. This, in turn, enables them to lead more active lives, participate in social activities, and experience a greater sense of independence. Many patients with heart pump devices report significant improvements in their physical and emotional well-being after receiving the device.

Heart pump devices also offer an alternative for patients who are not eligible for heart transplants. For various reasons, including age, comorbidities, or the availability of donor hearts, some patients may not be suitable candidates for heart transplantation. In these cases, heart pump devices serve as a long-term solution, providing mechanical support to the heart and allowing patients to live longer, healthier lives. This is particularly valuable for older patients or those with other medical conditions that complicate their candidacy for a transplant.

In addition to their role in treating heart failure, heart pump devices also help prevent complications related to other cardiovascular conditions, such as cardiogenic shock or heart attacks. By providing mechanical circulatory support during these critical events, heart pump devices can stabilize patients and prevent further damage to the heart, improving overall survival rates and reducing the risk of long-term complications.

What Factors Are Driving the Growth of the Heart Pump Devices Market?

Several key factors are driving the rapid growth of the heart pump devices market, including the increasing prevalence of heart failure, advancements in heart pump technology, the aging global population, and the rising demand for mechanical circulatory support. One of the primary drivers is the growing prevalence of heart failure worldwide. As populations age and lifestyle factors such as obesity, hypertension, and diabetes become more common, the number of individuals suffering from heart failure is steadily increasing. This has created a significant demand for advanced treatment options, such as heart pump devices, that can provide effective, long-term solutions for patients who are no longer responsive to medication or less invasive therapies.

Advancements in heart pump technology are another major factor fueling the growth of the market. The development of smaller, more durable, and less invasive devices has made heart pumps more accessible to a broader range of patients, including those with less severe heart failure or those who may not have been candidates for older-generation devices. These technological improvements have also led to better patient outcomes, fewer complications, and increased survival rates, driving the adoption of heart pump devices in healthcare systems around the world.

The aging global population is also contributing to the growth of the heart pump devices market. As life expectancy continues to rise, the incidence of age-related cardiovascular conditions, including heart failure, is increasing. Older patients are more likely to suffer from conditions that weaken the heart, making them prime candidates for heart pump devices. With the number of elderly individuals projected to grow significantly over the coming decades, the demand for heart pumps as a treatment option for age-related heart failure is expected to rise.

The rising demand for mechanical circulatory support in both short-term and long-term scenarios is another factor driving market growth. Heart pump devices are increasingly being used in critical care settings, such as during high-risk cardiac surgeries or for patients recovering from heart attacks or cardiogenic shock. The ability of heart pump devices to stabilize patients and support recovery has made them a valuable tool for cardiologists and cardiac surgeons, further driving their adoption in hospitals and healthcare facilities.

The growing focus on improving the quality of life for patients with chronic heart conditions is also propelling the market. As patients and healthcare providers seek solutions that not only extend life but also enhance day-to-day functioning, heart pump devices are being viewed as an essential option for managing heart failure. The improvements in patient mobility, reduction in symptoms, and overall better quality of life provided by these devices are significant motivators for their increasing use.

Additionally, government support and regulatory approvals for heart pump devices are expanding access to these life-saving technologies. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), are increasingly approving new heart pump devices and innovations, making these technologies more widely available to healthcare providers and patients. This regulatory support is crucial for driving market expansion and fostering the development of next-generation heart pump technologies.

In conclusion, the growth of the heart pump devices market is driven by the rising prevalence of heart failure, advancements in technology, the aging global population, and the increasing demand for mechanical circulatory support. As healthcare systems continue to adopt heart pump devices as a critical solution for managing advanced heart conditions, these devices will play an increasingly vital role in improving patient survival, reducing hospital readmissions, and enhancing the quality of life for heart failure patients worldwide.

Select Competitors (Total 13 Featured) -

  • Abbott Laboratories
  • Abiomed, Inc.
  • Berlin Heart GmbH
  • Fresenius Medical Care AG & Co. KGaA
  • Getinge AB
  • Jarvik Heart, Inc.
  • Medtronic PLC
  • ReliantHeart, Inc.
  • SynCardia Systems, LLC
  • Teleflex Incorporated
  • Terumo Europe NV

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Heart Pump Devices - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cardiovascular Diseases Propels Demand for Heart Pump Devices
    • Expansion of Heart Transplant Programs Strengthens Business Case for Temporary Heart Pump Devices
    • Increasing Focus on Minimally Invasive Procedures Spurs Adoption of Percutaneous Heart Pumps
    • Growing Aging Population Expands Addressable Market Opportunity for Heart Pump Devices
    • Expansion of Chronic Heart Failure Treatment Programs Bodes Well for Market Growth
    • Future Directions: Development of Fully Implantable Artificial Hearts Accelerates Market Potential
    • Growing Popularity of Bridge-to-Transplant Therapies Expands Adoption of Heart Pumps
    • Expansion of Cardiac Centers and Specialized Clinics Generates Demand for Heart Pump Devices
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Heart Pump Devices Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Heart Pump Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Heart Pump Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Heart Pump Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ventricular Assist Devices (VADs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Ventricular Assist Devices (VADs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Ventricular Assist Devices (VADs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Intra-aortic Balloon Pumps (IABPs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Intra-aortic Balloon Pumps (IABPs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Intra-aortic Balloon Pumps (IABPs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Total Artificial Heart (TAH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Total Artificial Heart (TAH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Total Artificial Heart (TAH) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Implantable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Implantable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Implantable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Extracorporeal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Extracorporeal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Extracorporeal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Bridge-to-Transplant (BTT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Bridge-to-Transplant (BTT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Bridge-to-Transplant (BTT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Bridge-to-Candidacy (BTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Bridge-to-Candidacy (BTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Bridge-to-Candidacy (BTC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Destination Therapy (DT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Destination Therapy (DT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Destination Therapy (DT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • JAPAN
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • CHINA
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • EUROPE
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Heart Pump Devices by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Heart Pump Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • FRANCE
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • GERMANY
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Heart Pump Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Heart Pump Devices by Product - Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Heart Pump Devices by Product - Percentage Breakdown of Value Sales for Ventricular Assist Devices (VADs), Intra-aortic Balloon Pumps (IABPs) and Total Artificial Heart (TAH) for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Heart Pump Devices by Type - Implantable and Extracorporeal - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Heart Pump Devices by Type - Implantable and Extracorporeal Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Heart Pump Devices by Type - Percentage Breakdown of Value Sales for Implantable and Extracorporeal for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Heart Pump Devices by Therapy - Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Heart Pump Devices by Therapy - Percentage Breakdown of Value Sales for Bridge-to-Transplant (BTT), Bridge-to-Candidacy (BTC), Destination Therapy (DT) and Other Therapies for the Years 2014, 2024 & 2030

IV. COMPETITION